NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

The Latest Regenerative Medicine Articles from Streetwise Reports


Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Research Report
  ()
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. read more >

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

  ()
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. read more >

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

Research Report
  ()
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. read more >

Three COVID-19 Patients Treated with PLX Cells

Research Report
  ()
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. read more >
Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts